Josu de la Fuente,1 Andre Baruchel,2 Andrea Biondi,3 Eveline de Bont,4 Marie-Francoise Dresse,5 Meinolf Suttorp6 and
Frederic Millot7 on behalf of the International BFM Group (iBFM) Study Group Chronic Myeloid Leukaemia Committee
Paediatrics Department, Saint Mary Hospital, London, UK, 2Department of Paediatric Haematology, Hopital Robert Debre, Paris,
France, 3 M. Tettamanti Research Centre, Paediatrics Department, University of Milano-Bicocca, Monza, Italy, 4 Department of Paediatric Oncology, Beatrix Children’s Hospital, Groningen, the Netherlands, 5 Department of Paediatric Haematology-Oncology, CHR La Citadelle, Liege, Belgium, 6
Tettamanti Research Centre, Paediatrics Department, University of Milano-Bicocca, Monza, Italy, 4 Department of Paediatric Oncology, Beatrix Children’s Hospital, Groningen, the Netherlands, 5 Department of Paediatric Haematology-Oncology, CHR La Citadelle, Liege, Belgium, 6
Department of Paediatric Haematology & Oncology, University Hospital, Technical University Dresden, Dresden, Germany and 7 Department of Paediatric Oncology, CHU Poitiers, Poitiers, France